A A Alali1, P B Hanagandi2, P J Maralani3. 1. From the Division of Neuroradiology (A.A.A.), King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia aliak@ksau-hs.edu.sa. 2. Department of Medical Imaging (P.B.H.), King Abdulaziz Medical City NGHA, Riyadh, Saudi Arabia. 3. Division of Neuroradiology (P.J.M.), Department of Medical Imaging, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Abstract
BACKGROUND AND PURPOSE: The use of gadolinium-based contrast agents contributes to the cost of MR imaging and prolongs image-acquisition time. There are also recent concerns regarding gadolinium deposition, particularly in patients who require frequent follow-up MRIs. The purpose of this study was to assess whether gadolinium-based contrast agents are needed during MR imaging follow-up for unoperated pituitary macroadenoma. MATERIALS AND METHODS: A total of 105 patients with unoperated pituitary macroadenoma who underwent follow-up MR imaging of the sella were included in this retrospective study. The craniocaudal dimension, cavernous sinus invasion grading, and optic pathway compression were assessed independently on coronal T2WI and compared with coronal T1-weighted images with gadolinium-based contrast agents (T1 postcontrast images). The agreement between the T2WI and T1 postcontrast images for the craniocaudal dimension was assessed using the intraclass correlation coefficient; for the cavernous sinus invasion and optic pathway compression, it was assessed using κ statistics. RESULTS: There was excellent agreement for the craniocaudal dimensions between T2WI and T1 postcontrast images (intraclass correlation coefficient = 0.96, P < .001; 95% CI, 0.84-0.99). Additionally, there was almost-perfect agreement between cavernous sinus invasion and optic pathway compression between T2WI and T1 postcontrast images, with κ = 0.95 and 0.84, respectively (P < .001). CONCLUSIONS: MR imaging of the sella without the use of gadolinium-based contrast agents could potentially be considered for the follow-up of unoperated pituitary macroadenomas. This choice can reduce the MR imaging examination cost and acquisition time and avoids potential adverse effects of gadolinium-based contrast agents.
BACKGROUND AND PURPOSE: The use of gadolinium-based contrast agents contributes to the cost of MR imaging and prolongs image-acquisition time. There are also recent concerns regarding gadolinium deposition, particularly in patients who require frequent follow-up MRIs. The purpose of this study was to assess whether gadolinium-based contrast agents are needed during MR imaging follow-up for unoperated pituitary macroadenoma. MATERIALS AND METHODS: A total of 105 patients with unoperated pituitary macroadenoma who underwent follow-up MR imaging of the sella were included in this retrospective study. The craniocaudal dimension, cavernous sinus invasion grading, and optic pathway compression were assessed independently on coronal T2WI and compared with coronal T1-weighted images with gadolinium-based contrast agents (T1 postcontrast images). The agreement between the T2WI and T1 postcontrast images for the craniocaudal dimension was assessed using the intraclass correlation coefficient; for the cavernous sinus invasion and optic pathway compression, it was assessed using κ statistics. RESULTS: There was excellent agreement for the craniocaudal dimensions between T2WI and T1 postcontrast images (intraclass correlation coefficient = 0.96, P < .001; 95% CI, 0.84-0.99). Additionally, there was almost-perfect agreement between cavernous sinus invasion and optic pathway compression between T2WI and T1 postcontrast images, with κ = 0.95 and 0.84, respectively (P < .001). CONCLUSIONS: MR imaging of the sella without the use of gadolinium-based contrast agents could potentially be considered for the follow-up of unoperated pituitary macroadenomas. This choice can reduce the MR imaging examination cost and acquisition time and avoids potential adverse effects of gadolinium-based contrast agents.
Authors: Salma H Hussein; Tayba S Wahedi; Naji Al Johani; Yasser A Hakami; Kamal Alzahrani; Mussa H AlMalki Journal: Hormones (Athens) Date: 2018-05-07 Impact factor: 2.885
Authors: Abdulrazag Ajlan; Achal S Achrol; Abdulrahman Albakr; Abdullah H Feroze; Erick M Westbroek; Peter Hwang; Griffith R Harsh Journal: J Neurol Surg B Skull Base Date: 2017-01-23
Authors: Shereen Ezzat; Sylvia L Asa; William T Couldwell; Charles E Barr; William E Dodge; Mary Lee Vance; Ian E McCutcheon Journal: Cancer Date: 2004-08-01 Impact factor: 6.860
Authors: Khalid S Aljabri; Samia A Bokhari; Faisal Y Assiri; Muneera A Alshareef; Patan M Khan Journal: Ann Saudi Med Date: 2016 Sep-Oct Impact factor: 1.526